Discover how a new human glioma cell line is transforming our understanding of brain cancer and opening new pathways for treatment
Explore the DiscoveryImagine a 23-year-old patient undergoing brain surgery for what appears to be a low-grade tumor. Under the microscope, the tissue looks relatively calm, classified as a WHO grade II fibrous astrocytoma. Yet hidden within this seemingly manageable tumor lies a special group of cells—so powerful that just a handful can generate an entirely new tumor, resistant to conventional therapies and capable of invading healthy brain tissue with ruthless efficiency.
This isn't science fiction; it's the reality of glioma stem cells (GSCs), and they're changing everything we know about brain cancer.
For decades, cancer researchers operated under a simple assumption: all tumor cells have similar ability to grow and spread. We now know this is fundamentally wrong. Like a queen bee in a hive, a tiny population of stem-like cells exists within gliomas that drive tumor formation, progression, and recurrence 7 . These GSCs possess an eerie ability to self-renew, differentiate into various cell types, and resist conventional treatments.
Glioblastoma, the most aggressive brain tumor, has a median survival of just 12-15 months after diagnosis despite surgical removal, chemotherapy, and radiation 3 .
The cancer stem cell theory represents a paradigm shift in oncology. It proposes that tumors, like healthy tissues, are organized hierarchically, with a small number of stem-like cells at the apex. These cells possess three defining properties:
The ability to create copies of themselves indefinitely
The capacity to differentiate into multiple cell types that make up the tumor's heterogeneous population
The power to initiate new tumors when transplanted into animal models 7
In gliomas, these GSCs are responsible for tumor initiation, progression, resistance to therapy, and eventual recurrence 7 . They represent a double threat: not only do they drive tumor growth, but they also survive treatments that kill ordinary cancer cells, eventually leading to tumor regrowth.
If GSCs are the key to understanding brain cancer, how do researchers identify them? The answer lies in specific molecular markers on their surface.
CD133 was the first marker identified for GSCs. Seminal studies showed that as few as 100 CD133+ cells could generate tumors in immunocompromised mice that recapitulated the heterogeneity of the original tumor .
However, the CD133 story soon became complicated. Some studies found that CD133-negative cells could also form tumors, and the expression of CD133 appeared dynamic, changing under different conditions like hypoxia or metabolic stress 7 .
Enter A2B5, a different type of marker that recognizes c-series gangliosides—complex glycolipids with three sialic acids that are abundant in the brain 2 9 .
Research has revealed that A2B5 may be an even more reliable marker for GSCs than CD133. Studies demonstrate that all types of gliomas express A2B5, and that only A2B5+ cells—not A2B5- cells—can generate tumors after implantation in animal models 2 .
While numerous cell lines existed for studying glioblastoma (GBM), the most aggressive brain tumor, permanent lines from low-grade gliomas were much rarer. This represented a significant gap in our research capabilities, as understanding the progression from low-grade to high-grade tumors is crucial for developing early intervention strategies.
The SHG-139 cell line changed this landscape. Established from the surgical resection of brain tumor tissue from a 23-year-old male patient diagnosed with WHO grade II fibrous astrocytoma, SHG-139 filled a critical void in glioma research 1 4 .
This molecular profile suggested a relatively slow-growing tumor, consistent with its grade II classification 4 .
What makes SHG-139 so valuable to researchers? This cell line possesses several distinctive features:
SHG-139 cells grow significantly within 24 hours, with rapid growth within the first 48 hours 4
The cells contain 68 chromosomes with irregular distortion 1
Positive for A2B5, GalC, GFAP, S-100, and vimentin 4
Can give rise to stem-like cells (SHG-139S) under specific culture conditions 1
The transformation of SHG-139 cells into stem-like SHG-139S cells required careful manipulation of the cells' environment. Here's how the researchers accomplished this feat:
Researchers first cultured primary cells from fresh tumor tissues, observing that the glioma cells grew slowly for the first five generations before accelerating their growth rate by the seventh generation 1
At the 20th generation, cells were cultured in neural stem cell medium (NSCM) containing specific growth factors. After one week in suspension, glioma stem-like cell spheres began to form 1
During passaging, researchers collected only the suspended cell spheres and discarded adherent cells. By the 10th generation, a large number of glioma stem-like spheres grew in suspension 1
The researchers used various techniques to characterize both SHG-139 and SHG-139S cells, including immunofluorescence staining, cell proliferation assays, chromosome analysis, and animal xenograft studies 4
The results of these experiments revealed striking differences between the original SHG-139 cells and their stem-like counterparts:
| Marker | SHG-139 | SHG-139S | Significance |
|---|---|---|---|
| A2B5 | Positive | Positive (84.12 ± 9.96%) | Identifies glial precursor cells and glioma stem cells |
| CD133 | Not reported | Rarely positive (4.2 ± 1.29%) | Traditional stem cell marker with limitations in GSCs |
| Nestin | Not reported | Positive (73.86 ± 5.01%) | Neural stem cell marker indicating immature state |
| NG2 | Not reported | Positive (49.12 ± 12.83%) | Neuron-glia antigen marker for progenitor cells |
| GFAP | Positive | Not typically expressed | Differentiated astrocyte marker |
| IDH1R132H | Positive | Negative | Mutation common in lower-grade gliomas |
When researchers implanted these cells into animal models, even more striking differences emerged:
Critically, the SHG-139S xenograft tumors were more aggressive than those from SHG-139, highlighting the increased danger posed by the stem-like cells 1 .
Further research revealed that even within the SHG-139S line, different subpopulations existed with specialized functions:
| Characteristic | A2B- Cells | A2B5+ Cells |
|---|---|---|
| Proliferation Index | Higher | Lower |
| Self-renewal Ability | Higher | Lower |
| Angiogenic Capacity | Increased | Reduced |
| Invasive Potential | Lower | Higher |
| MMP2/MMP9 Expression | Lower | Higher |
| E-cadherin Expression | Higher | Lower |
This fascinating division of labor between subpopulations helps explain how tumors can maintain both growth capacity (through A2B5- cells) and invasive potential (through A2B5+ cells) 8 .
Studying glioma stem cells requires specialized tools and reagents. Here are some essential components of the glioma researcher's toolkit:
| Research Tool | Specific Example | Function in Research |
|---|---|---|
| Cell Culture Media | DMEM/F12 with growth factors | Supports stem cell growth and maintenance |
| Growth Factors | EGF, bFGF | Promotes proliferation and stemness maintenance |
| Stem Cell Markers | A2B5, CD133, Nestin | Identifies and isolates stem cell populations |
| Separation Tools | Magnetic-activated cell sorting (MACS) | Separates cell subpopulations for individual study |
| Animal Models | Nude mice | Tests tumorigenicity of cells in living organisms |
| Staining Agents | Immunofluorescence antibodies | Visualizes protein expression in cells and tissues |
Working with glioma stem cells presents unique technical challenges. Maintaining these cells requires specific conditions that prevent them from differentiating spontaneously.
Researchers use serum-free media supplemented with specific growth factors like EGF and bFGF to maintain the stem-like state 8 .
Serum-Free Media
Growth Factors
Controlled Environment
Identifying true stem cells requires multiple markers rather than relying on a single indicator. The research on SHG-139S demonstrated that GSCs can be A2B5+/CD133-, challenging the earlier focus on CD133 as the definitive marker 1 4 .
The establishment of the SHG-139 cell line and its stem-like counterpart SHG-139S provides researchers with valuable tools for probing the mysteries of glioma biology. These cell lines offer several key advantages for research:
Because SHG-139 originates from a low-grade glioma but can generate aggressive stem cells, it provides a unique model for studying how low-grade tumors progress to higher grades 1
GSCs are notoriously resistant to conventional therapies. Having a reliable cell line that contains these cells allows researchers to dissect the mechanisms behind this resistance 7
The presence of different subpopulations within SHG-139S mirrors the heterogeneity seen in actual tumors, allowing researchers to study how different cell types within a tumor interact 8
The identification of A2B5 as a key marker for GSCs opens exciting possibilities for developing more effective treatments:
Drugs or immunotherapies could be developed to specifically target A2B5+ cells, eliminating the most dangerous component of the tumor while sparing healthy tissues 2
Since GSCs are thought to be responsible for tumor recurrence after treatment, therapies that successfully eliminate these cells could significantly improve long-term outcomes for patients 7
Treatments that target both differentiated tumor cells and GSCs could provide more comprehensive tumor control than current approaches
Research into GSCs has revealed several key pathways that maintain their stemness, including EGFR, PI3K/AKT/mTOR, Wnt, Notch, and STAT3 pathways . These pathways represent additional potential targets for therapeutic intervention.
The discovery of glioma stem cells has fundamentally transformed our understanding of brain cancer, and the establishment of cell lines like SHG-139 that can generate A2B5+ stem cells provides researchers with powerful tools to combat this devastating disease.
These discoveries represent more than just incremental advances—they signify a paradigm shift in how we view and approach brain tumors.
As research continues, scientists are working to translate these laboratory findings into clinical applications that could benefit patients.
The fight against glioma is far from over, but with innovative approaches targeting the root of the problem, there is renewed hope for more effective treatments.
The humble A2B5 marker, once just an anonymous identifier on cell surfaces, may well hold the key to unlocking better outcomes for brain cancer patients worldwide.
References will be added here in the required format.